Creative Medical Technology Holdings, Inc. received Nasdaq notice on November 10, 2026 after its bid price stayed below $1.00 per share for 30 business days. It has until May 10, 2027 to regain compliance for at least ten consecutive business days.
CELZ · Creative Medical Technology Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Creative Medical Technology Holdings, Inc. stockholders will vote on December 28, 2026 to elect five directors and approve an evergreen provision adding up to 5% of outstanding common shares annually from January 1, 2027 through January 1, 2031.
Creative Medical Technology Holdings reported no revenue and a $2,663,478 net loss for the three months ended September 30, 2026, versus $1,235,934 a year earlier. Available cash and US Treasuries totaled $6,845,741.
On September 24, 2026, Creative Medical Technology Holdings, Inc. purchased 4,000,000 BioDefense, Inc. shares for $200,000 and 1,000,000 company shares, increasing its ownership to 16,000,000 shares, or 80%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CELZ
this stock
Creative Medical Technology Holdings, Inc.
|
$3.34M | -77.6% | -45.5% | — | 0.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 15
Creative Medical Technology Holdings, Inc. received Nasdaq notice on November 10, 2026 after its bid price stayed below $1.00 per share for 30 business days. It has until May 10, 2027 to regain compliance for at least ten consecutive business days.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CELZ | -28.6% | -43.2% | -80.4% | -32.8% | -77.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -23.2% | -36.9% | -74.8% | -27.6% | -82.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.